Articles from Bonerge
In 2025, Bonerge initiated a clinical trial (Registration #NCT06990256) investigating the effects of Urolithin A and Fisetin on sleep quality, targeting sleep disorders through the lens of ageing biology.
By Bonerge · Via Business Wire · July 8, 2025

Bonerge announced the initiation of its clinical trial, focusing on Fisetin, Urolithin A, and Ergothioneine. Involving 108 participants, this trial aims to evaluate their combined effects on skin health and organ rejuvenation when taking orally, providing more reliable options for the market.
By Bonerge · Via Business Wire · January 8, 2025

In 2024, Bonerge's premium fisetin branded ingredient, BeFisetin®, initiated the SA-GRAS (Self-Affirmed Generally Recognized As Safe) certification process, with completion expected in February 2025. This certification underscores Bonerge's unwavering commitment to product safety, quality control and serves as a key milestone in its expansion into the global fisetin market.
By Bonerge · Via Business Wire · December 31, 2024

Bonerge is excited to announce the initiation of clinical trials for its high-quality brand ingredients, including GlucoSober and BeFisetin. These trials aim to substantiate the efficacy and safety of the products, providing more reliable options for the market.
By Bonerge · Via Business Wire · July 31, 2024